PharmaVentures has been engaged to act as an advisor to Volition to help secure licensing deals with industry leaders for both Nu.Q® Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR™ – a novel detection method for liquid biopsy in cancer and potentially other diseases. Adrian Dawkes, Managing Director, PharmaVentures, said: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving li ...